Berkeley, Calif. – April 18, 2023 − IMVARIA Inc., a software-as-medical-device (SaMD) company pioneering AI-driven digital biomarker solutions, today announced that four presentations utilizing the company’s technology will be featured at the upcoming American Thoracic Society 2023 International Conference (ATS 2023), held in Washington, DC from May 19-24.
“Our vision at IMVARIA is to transform clinical decision-making into data science that can help physicians more accurately and rapidly diagnose patients, and therefore, potentially reduce the need for invasive biopsy testing,” said Joshua Reicher, MD, CEO of IMVARIA, and Michael Muelly, MD, CTO of IMVARIA. “These four presentations at ATS demonstrate our ability to leverage AI, machine learning and deep-learning models in ways that may ultimately help optimize patient outcomes through novel digital biomarkers.”
Details for the four presentations can be found below:
Chest Computed Tomography Machine Learning Classifier for Idiopathic Pulmonary Fibrosis Predicts Mortality in Interstitial Lung Diseases
Oral Presentation
Mini Symposium, Session D91 - Looking for the Crystal Ball: Biomarkers to Predict Disease Progression and Mortality in ILD
May 24, 2023, 12:00 PM - 2:00 PM
Walter E Washington Convention Center, Ballroom A (Level 3)
Development and Validation of a CT-based Deep Learning Algorithm to Augment Non-invasive Diagnosis of Idiopathic Pulmonary Fibrosis
Poster Presentation #812
Poster Discussion, Session A23 - Leveraging Imaging and Biosamples to Improve Diagnosis and Risk Prediction in ILA and ILD
May 21, 2023, 9:00 AM - 11:00 AM
Walter E. Washington Convention Center, Room 209 A-C (Level 2)
Predicting Interstitial Pulmonary Fibrosis Using a Machine Learning Classifier in Cases Without Definite or Probable Usual Interstitial Pneumonia Pattern on Computed Tomography
Poster Presentation #P556
Thematic Poster Session C39. Care and Evaluation of Patients with Interstitial Lung Disease
May 23, 2023, 11:30 AM - 1:15 PM
Walter E. Washington Convention Center, Area E, Hall C (Lower Level)
A Machine Learning System to Predict Diagnosis of Idiopathic Pulmonary Fibrosis Non-Invasively in Challenging Cases
Poster Presentation #P557
Thematic Poster Session C39. Care and Evaluation of Patients with Interstitial Lung Disease
May 23, 2023, 11:30 AM - 1:15 PM
Walter E. Washington Convention Center, Area E, Hall C (Lower Level)
IMVARIA is a software-as-medical-device (SaMD) company pioneering AI-driven digital biomarker solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease and reduce the need for invasive biopsy testing. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates its Digital Biomarker Lab with automated, machine-learning algorithm technology to transform clinical decision-making into data science. IMVARIA is based in Berkeley, CA. For more information, go to www.imvaria.com.
Anthony Petrucci
Bioscribe
anthony@bioscribe.com
512-581-5442
IMVARIA brings artificial intelligence to imaging and lab data,
re-imagining clinical assessments in serious diseases.
With FDA Breakthrough Device Designation for the leading
digital biomarker in lung fibrosis.
IMVARIA's lead digital biomarker, Fibresolve, demonstrates the power of IMVARIA's innovation to serve as adjunct in assessment of interstitial lung disease (ILD) including idiopathic pulmonary fibrosis (IPF), potentially avoiding expensive, invasive surgical testing.* Fibresolve uses AI to analyze CT imaging for specific, novel patterns.
Background in IPF:
In the challenging condition of IPF, high-risk patients face high rates of mortality and massive costs with surgical diagnostics. The FDA has already granted Fibresolve with Breakthrough Devices Designation to expedite the medical community's access to more effective non-invasive diagnosis for this life-threatening disease.
Advancing Research in IPF:
Fibresolve met clinical study endpoints for increasing non-invasive diagnosis in challenging cases by 3.2x. Results pending publication.
*Investigational-use only
The Digital Biomarker Lab is a centralized, cloud-based digital lab that operates in a broadly similar fashion to that of a specialty CLIA lab–except that we handle data rather than blood or tissue samples. Clinicians, health systems, and clinical trialists transmit cases to the Lab and IMVARIA analyzes the cases and returns reports with results in minutes. The system capacity crosses imaging modalities (eg. CT, MRI), organ systems, and data types (lab results), and follows international standards for quality compliance (eg. ISO 13485). Projects in new disease areas take weeks to months instead of years, and modern architecture supports deep learning, fusion, and multi-dimensional / multi-modal models.
Estimated availability in 2023--currently available for research use. IMVARIA is on the front lines of utilizing digital data to improve patient outcomes. Leveraging diverse clinical and laboratory datasets to identify distinct disease signatures addresses many of the challenges with standard diagnostic methods.
Additionally, quantitative-only techniques, including many prognostic calculators, rarely capture the complexities and variance of disease phenotypes. With in-house data in more than 30,000 patients, our systems drive new insights in predicting outcomes and helping better understand risks.
Through analysis of wide-ranging data types and data sources (including patient registries, clinical trials, and public datasets) the company’s next-generation data science optimizes for consistent and accurate disease assessments and predictions. Whether it is optimizing study enrollment characteristics, better risk-stratifying patients at trial enrollment, or developing predictions for treatment response, IMVARIA can help.
We are proud to work with these partners:
Led by dual physician-engineers from Google and Stanford Health Care, IMVARIA’s pioneering work with AI-driven digital biomarkers is redefining how to approach complex diseases more effectively.
Our digital biomarkers provide unique insights into diagnosis and disease assessment, driven by AI and high quality captured clinical data. Imaging and lab results form the basis for more complex analysis of multi-modal clinical data.
The company is empowering physicians to make the best-informed clinical decisions through the precise application of our digital biomarker technology and data science, taking on the greatest challenges in serious and rare diseases.
IMVARIA's Software-as-Medical-Device (SaMD) tools are transforming the use of digital biomarkers for clinical decision-making and therapeutic development-focused clinical trials.
Based in Berkeley, CA, IMVARIA is pioneering AI-driven digital biomarker solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease and reduce the need for invasive biopsy testing. The company is also using its technology to support biopharmaceutical partners through optimizing pre-trial patient stratification and identifying new digital biomarker opportunities for therapeutics development.
Prior experience includes work in Google's AI group, multiple publications in machine learning in medicine, and extensive experience writing code. Dr. Reicher is on clinical faculty as a radiologist and computer science researcher at Stanford / Palo Alto VA.
Prior experience includes work as a Product Manager at Google Cloud's Healthcare group, co-founding of both imaging and network security start-ups, and extensive experience writing code. Dr. Muelly is on clinical faculty as a radiologist and computer science researcher at Stanford.
Leading pulmonary and rare disease expert at Stanford. Board-certified in pulmonary and critical care medicine. Key opinion leader and clinical trials principal investigator.
October 6, 2021
As we’ve seen with the COVID-19 pandemic, diagnostics deliver vital information that enable health providers to properly triage patients and provide the best treatment according to their illness...
June 10, 2021
The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health technology companies chosen for their innovative technologies...
June 15, 2021
MedTech Innovator today revealed the 50 startups it selected to partake in its flagship showcase and accelerator program. The four-month program offers the startups visibility and access...
October 6, 2021
Transforming Diagnostics with Machine Learning and Digital BiomarkersAs we’ve seen with the COVID-19 pandemic, diagnostics deliver vital information that enable health providers to properly triage patients and provide the best treatment according to their illness...
The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health technology companies chosen for their innovative technologies...
MedTech Innovator today revealed the 50 startups it selected to partake in its flagship showcase and accelerator program. The four-month program offers the startups visibility and access...
As a VC-backed health tech company with a strong clinical and technical founding team with backgrounds at Stanford and Google, we are growing core engineering and commercial teams to build and deploy a medical-grade software platform. You'll get to help shape the trajectory of this mission-driven company, while receiving a hands-on education in building and commercializing medical AI.
IMVARIA is a remote-first company: we welcome flexible schedules, work from home, and digital collaboration. Join us!